Charles Schwab’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.7M Buy
1,212,407
+24,679
+2% +$238K ﹤0.01% 1892
2026
Q1
$8.81M Sell
1,187,728
-29,424
-2% -$310K ﹤0.01% 2166
2025
Q4
$14.3M Buy
1,217,152
+84,577
+7% +$912K ﹤0.01% 1952
2025
Q3
$8.74M Sell
1,132,575
-55,027
-5% -$385K ﹤0.01% 2173
2025
Q2
$8.68M Buy
1,187,602
+60,706
+5% +$490K ﹤0.01% 2087
2025
Q1
$10.7M Sell
1,126,896
-34,456
-3% -$430K ﹤0.01% 1922
2024
Q4
$19.1M Buy
1,161,352
+26,701
+2% +$415K ﹤0.01% 1729
2024
Q3
$16.7M Buy
1,134,651
+57,677
+5% +$902K ﹤0.01% 1788
2024
Q2
$14.9M Sell
1,076,974
-843
-0.1% -$12K ﹤0.01% 1837
2024
Q1
$16.9M Buy
1,077,817
+31,252
+3% +$483K ﹤0.01% 1707
2023
Q4
$16.9M Buy
1,046,565
+41,794
+4% +$684K ﹤0.01% 1688
2023
Q3
$12.4M Buy
1,004,771
+16,451
+2% +$245K ﹤0.01% 1801
2023
Q2
$15.9M Buy
988,320
+16,144
+2% +$266K ﹤0.01% 1652
2023
Q1
$16.9M Sell
972,176
-3,885
-0.4% -$55.3K 0.01% 1594
2022
Q4
$9.02M Buy
976,061
+30,231
+3% +$282K ﹤0.01% 1920
2022
Q3
$8.14M Buy
945,830
+12,583
+1% +$125K ﹤0.01% 1952
2022
Q2
$7.61M Buy
933,247
+16,064
+2% +$153K ﹤0.01% 1980
2022
Q1
$11.1M Buy
917,183
+20,596
+2% +$433K ﹤0.01% 1892
2021
Q4
$30.6M Buy
896,587
+18,538
+2% +$726K 0.01% 1248
2021
Q3
$42.4M Buy
878,049
+31,631
+4% +$1.46M 0.01% 990
2021
Q2
$38.2M Buy
846,418
+25,228
+3% +$1.12M 0.01% 1067
2021
Q1
$39.6M Buy
821,190
+51,651
+7% +$2.69M 0.01% 985
2020
Q4
$41.4M Sell
769,539
-15,139
-2% -$684K 0.02% 892
2020
Q3
$28.9M Sell
784,678
-8,027
-1% -$298K 0.01% 965
2020
Q2
$24.6M Buy
792,705
+98,047
+14% +$2.72M 0.01% 1035
2020
Q1
$19.2M Buy
694,658
+12,121
+2% +$363K 0.01% 1047
2019
Q4
$20M Buy
682,537
+15,873
+2% +$378K 0.01% 1215
2019
Q3
$12.7M Buy
666,664
+99,910
+18% +$2.34M 0.01% 1446
2019
Q2
$12.4M Buy
566,754
+52,594
+10% +$1.15M 0.01% 1456
2019
Q1
$10.5M Buy
514,160
+65,986
+15% +$1.15M 0.01% 1555
2018
Q4
$5.65M Buy
448,174
+67,066
+18% +$999K ﹤0.01% 1843
2018
Q3
$5.85M Buy
381,108
+82,066
+27% +$1.13M ﹤0.01% 1963
2018
Q2
$3.92M Sell
299,042
-6,953
-2% -$76.5K ﹤0.01% 2129
2018
Q1
$2.5M Buy
305,995
+8,949
+3% +$72.5K ﹤0.01% 2248
2017
Q4
$2.63M Buy
297,046
+86,006
+41% +$793K ﹤0.01% 2210
2017
Q3
$2.35M Buy
211,040
+11,386
+6% +$111K ﹤0.01% 2233
2017
Q2
$1.79M Buy
199,654
+1,235
+0.6% +$9.8K ﹤0.01% 2255
2017
Q1
$1.57M Buy
198,419
+11,115
+6% +$90.5K ﹤0.01% 2280
2016
Q4
$1.61M Buy
187,304
+10,010
+6% +$85.7K ﹤0.01% 2264
2016
Q3
$1.46M Buy
177,294
+87,406
+97% +$733K ﹤0.01% 2280
2016
Q2
$723K Hold
89,888
﹤0.01% 2455
2016
Q1
$606K Hold
89,888
﹤0.01% 2505
2015
Q4
$708K Hold
89,888
﹤0.01% 2500
2015
Q3
$516K Buy
89,888
+20,400
+29% +$126K ﹤0.01% 2613
2015
Q2
$376K Buy
+69,488
New +$358K ﹤0.01% 2788
2014
Q2
Sell
-46,900
Closed -$163K 3121
2014
Q1
$163K Hold
46,900
﹤0.01% 2993
2013
Q4
$170K Hold
46,900
﹤0.01% 2991
2013
Q3
$143K Hold
46,900
﹤0.01% 2999
2013
Q2
$187K Buy
+46,900
New +$179K ﹤0.01% 2924

Other funds holding NEO

Charles Schwab's NEO Position: Q2 2026 in Review

Charles Schwab increased its NeoGenomics (NEO) stake by 2.1% in Q2 2026, buying an estimated $238K and bringing the position to 1,212,407 shares worth $17.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1892.

Charles Schwab first reported a position in NEO in Q2 2013 and has held it in 49 quarters since. The position peaked at $42.4M in Q3 2021. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • Charles Schwab held 1,212,407 shares of NeoGenomics worth $17.7M as of Q2 2026.
  • Charles Schwab bought 24,679 NeoGenomics shares in Q2 2026, an estimated $238K.
  • NeoGenomics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1892 holding.
  • Charles Schwab first reported a position in NeoGenomics in Q2 2013 and has held it in 49 quarters since.
  • Charles Schwab's NeoGenomics position peaked at $42.4M in Q3 2021.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.